Images (2)

Daunorubicin, liposomal

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Cytostatic agent.

Half-lifeThis section has been translated automatically.

11–27 h

IndicationThis section has been translated automatically.

HIV-infection-associated Kaposi sarcoma.

Pregnancy/nursing periodThis section has been translated automatically.

Contraindicated.

Dosage and method of useThis section has been translated automatically.

40 mg/m2 KO i.v. every 2 weeks.

Undesirable effectsThis section has been translated automatically.

Altogether few UAWs! Rarely alopecia, gastrointestinal disorders, disorders of hematopoiesis, fever, urticaria, angioedema, palmoplantar erxthrodysesthesia.

ContraindicationThis section has been translated automatically.

Hypersensitivity to anthracyclines or anthracenediones.

PreparationsThis section has been translated automatically.

Daunoblastine, DaunoXome

Note(s)This section has been translated automatically.

Remember! During the therapy and up to 6 months after contraception!

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer